Literature DB >> 10873957

Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis.

J S Smolen1, F C Breedveld, G R Burmester, B Combe, P Emery, J R Kalden, L Klareskog, R N Maini, R Numo, L B van De Putte, P L van Riel, V Rodriguez-Valverde.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10873957      PMCID： PMC1753196          DOI： 10.1136/ard.59.7.504

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  11 in total

Review 1.  The role of current strategies in the future treatment of rheumatoid arthritis.

Authors:  M E Weinblatt
Journal:  Rheumatology (Oxford)       Date:  1999-11       Impact factor: 7.580

2.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

3.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

Authors:  L W Moreland; S W Baumgartner; M H Schiff; E A Tindall; R M Fleischmann; A L Weaver; R E Ettlinger; S Cohen; W J Koopman; K Mohler; M B Widmer; C M Blosch
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

4.  Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; H Bijl; J N Woody
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

5.  Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.

Authors:  D M van der Heijde; P L van Riel; I H Nuver-Zwart; F W Gribnau; L B vad de Putte
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

6.  Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.

Authors:  D T Felson; J J Anderson; R F Meenan
Journal:  Arthritis Rheum       Date:  1992-10

7.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

8.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Authors:  M E Weinblatt; J M Kremer; A D Bankhurst; K J Bulpitt; R M Fleischmann; R I Fox; C G Jackson; M Lange; D J Burge
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

9.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Authors:  R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Davis; J D Macfarlane; C Antoni; B Leeb; M J Elliott; J N Woody; T F Schaible; M Feldmann
Journal:  Arthritis Rheum       Date:  1998-09

10.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; D Furst; C Goldsmith; L M Katz; R Lightfoot; H Paulus; V Strand
Journal:  Arthritis Rheum       Date:  1995-06
View more
  8 in total

1.  Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.

Authors:  Paul Emery; Maya Buch
Journal:  BMJ       Date:  2002-02-09

2.  Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors:  J S Smolen; E C Keystone; P Emery; F C Breedveld; N Betteridge; G R Burmester; M Dougados; G Ferraccioli; U Jaeger; L Klareskog; T K Kvien; E Martin-Mola; K Pavelka
Journal:  Ann Rheum Dis       Date:  2006-10-26       Impact factor: 19.103

Review 3.  Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible.

Authors:  T K Kvien; T Uhlig; I S Kristiansen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis.

Authors:  Ivan Jančić; Nevena Arsenović-Ranin; Mirjana Sefik-Bukilica; Sladjana Zivojinović; Nemanja Damjanov; Vesna Spasovski; Sanja Srzentić; Biljana Stanković; Sonja Pavlović
Journal:  Rheumatol Int       Date:  2012-12-12       Impact factor: 2.631

5.  Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.

Authors:  G J Wolbink; A E Voskuyl; W F Lems; E de Groot; M T Nurmohamed; P P Tak; B A C Dijkmans; L Aarden
Journal:  Ann Rheum Dis       Date:  2004-10-14       Impact factor: 19.103

Review 6.  Pursuit of optimal outcomes in rheumatoid arthritis.

Authors:  David L Scott
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

7.  Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.

Authors:  Margaret Wisłowska; Danuta Jakubicz
Journal:  Rheumatol Int       Date:  2007-01-18       Impact factor: 3.580

8.  Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis.

Authors:  Ivan Jančić; Mirjana Šefik-Bukilica; Slađana Živojinović; Nemanja Damjanov; Vesna Spasovski; Nikola Kotur; Kristel Klaassen; Sonja Pavlović; Biljana Bufan; Nevena Arsenović-Ranin
Journal:  J Med Biochem       Date:  2015-09-19       Impact factor: 3.402
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.